Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Rivastigmine Transdermal Patches Market by Type (4.6mg/24hr, 9.5mg/24hr, 13.3 mg/24hr), By Application (Alzheimer’s Disease, Parkinson, Other) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Rivastigmine Transdermal Patches Market by Type (4.6mg/24hr, 9.5mg/24hr, 13.3 mg/24hr), By Application (Alzheimer’s Disease, Parkinson, Other) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 131702 3300 Pharma & Healthcare 377 235 Pages 4.8 (41)

The global Rivastigmine transdermal patches market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The major factors driving the growth of this market are increasing prevalence of Alzheimer's disease and Parkinson's disease, increasing geriatric population, and rising awareness about the benefits of transdermal patches. However, high cost associated with these drugs may hamper the growth of this market in some regions. The global Rivastigmine transdermal patches market is segmented on the basis of type (4.6mg/24hr, 9.5mg/24hr, 13.3 mg/24hr), by application (Alzheimer's Disease and Parkinson), and by region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa). The 4.6mg/24hr segment accounted for a significant share in 2017 owing to its low price as compared to other types which are priced higher due to their higher dosage strength per patch or tablet form; however it has been observed that there is an increase in demand for higher dosage strength per patch or tablet form which will lead to an increase in demand for 9-13 mg/24hr segments over time as well as increased use cases such as treatment for Parkinson's disease which will also lead to an increase in demand for 13-18 mg/24hr segments over time leading up till 2030 when all three segments are expected to be equally popular among consumers globally.

  1. The global population is aging and the number of people with dementia is increasing.
  2. Rivastigmine transdermal patches are a treatment for Alzheimer's disease, which has been shown to be effective in improving cognitive function in patients with mild to moderate Alzheimer's disease, as well as those who have had a stroke or traumatic brain injury (TBI).
  3. Rivastigmine transdermal patches are available by prescription only and require regular monitoring by healthcare professionals.

Industry Growth Insights published a new data on “Rivastigmine Transdermal Patches Market”. The research report is titled “Rivastigmine Transdermal Patches Market research by Types (4.6mg/24hr, 9.5mg/24hr, 13.3 mg/24hr), By Applications (Alzheimer's Disease, Parkinson, Other), By Players/Companies Novartis, Luye Pharma, ...”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Rivastigmine Transdermal Patches Market Research Report

By Type

4.6mg/24hr, 9.5mg/24hr, 13.3 mg/24hr

By Application

Alzheimer's Disease, Parkinson, Other

By Companies

Novartis, Luye Pharma, ...

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year


Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year


Number of Pages


Number of Tables & Figures


Customization Available

Yes, the report can be customized as per your need.

Global Rivastigmine Transdermal Patches Industry Outlook

Global Rivastigmine Transdermal Patches Market Report Segments:

The global Rivastigmine Transdermal Patches market is segmented on the basis of:


4.6mg/24hr, 9.5mg/24hr, 13.3 mg/24hr

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.


Alzheimer's Disease, Parkinson, Other

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Novartis
  2. Luye Pharma
  3. ...

Global Rivastigmine Transdermal Patches Market Overview

Highlights of The Rivastigmine Transdermal Patches Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. 4.6mg/24hr
    2. 9.5mg/24hr
    3. 13.3 mg/24hr
  1. By Application:

    1. Alzheimer's Disease
    2. Parkinson
    3. Other
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Rivastigmine Transdermal Patches Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Rivastigmine Transdermal Patches Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?

Rivastigmine transdermal patches are a type of medication patch that is placed on the skin. Rivastigmine patches work by slowing down the nerve impulses in the brain. This helps to improve symptoms of Alzheimer's disease and other memory problems.

Some of the key players operating in the rivastigmine transdermal patches market are Novartis, Luye Pharma.

The rivastigmine transdermal patches market is expected to register a CAGR of 5.5%.

1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Rivastigmine Transdermal Patches Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Rivastigmine Transdermal Patches Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Rivastigmine Transdermal Patches Market - Supply Chain
   4.5. Global Rivastigmine Transdermal Patches Market Forecast
      4.5.1. Rivastigmine Transdermal Patches Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Rivastigmine Transdermal Patches Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Rivastigmine Transdermal Patches Market Absolute $ Opportunity

5. Global Rivastigmine Transdermal Patches Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Rivastigmine Transdermal Patches Market Size and Volume Forecast by Type
      5.3.1. 4.6mg/24hr
      5.3.2. 9.5mg/24hr
      5.3.3. 13.3 mg/24hr
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Rivastigmine Transdermal Patches Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Rivastigmine Transdermal Patches Market Size and Volume Forecast by Application
      6.3.1. Alzheimer's Disease
      6.3.2. Parkinson
      6.3.3. Other
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Rivastigmine Transdermal Patches Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Rivastigmine Transdermal Patches Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Rivastigmine Transdermal Patches Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Rivastigmine Transdermal Patches Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Rivastigmine Transdermal Patches Demand Share Forecast, 2019-2029

9. North America Rivastigmine Transdermal Patches Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Rivastigmine Transdermal Patches Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Rivastigmine Transdermal Patches Market Size and Volume Forecast by Application
      9.4.1. Alzheimer's Disease
      9.4.2. Parkinson
      9.4.3. Other
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Rivastigmine Transdermal Patches Market Size and Volume Forecast by Type
      9.7.1. 4.6mg/24hr
      9.7.2. 9.5mg/24hr
      9.7.3. 13.3 mg/24hr
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Rivastigmine Transdermal Patches Demand Share Forecast, 2019-2029

10. Latin America Rivastigmine Transdermal Patches Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Rivastigmine Transdermal Patches Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Rivastigmine Transdermal Patches Market Size and Volume Forecast by Application
      10.4.1. Alzheimer's Disease
      10.4.2. Parkinson
      10.4.3. Other
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Rivastigmine Transdermal Patches Market Size and Volume Forecast by Type
      10.7.1. 4.6mg/24hr
      10.7.2. 9.5mg/24hr
      10.7.3. 13.3 mg/24hr
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Rivastigmine Transdermal Patches Demand Share Forecast, 2019-2029

11. Europe Rivastigmine Transdermal Patches Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Rivastigmine Transdermal Patches Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Rivastigmine Transdermal Patches Market Size and Volume Forecast by Application
      11.4.1. Alzheimer's Disease
      11.4.2. Parkinson
      11.4.3. Other
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Rivastigmine Transdermal Patches Market Size and Volume Forecast by Type
      11.7.1. 4.6mg/24hr
      11.7.2. 9.5mg/24hr
      11.7.3. 13.3 mg/24hr
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Rivastigmine Transdermal Patches Demand Share, 2019-2029

12. Asia Pacific Rivastigmine Transdermal Patches Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Rivastigmine Transdermal Patches Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Rivastigmine Transdermal Patches Market Size and Volume Forecast by Application
      12.4.1. Alzheimer's Disease
      12.4.2. Parkinson
      12.4.3. Other
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Rivastigmine Transdermal Patches Market Size and Volume Forecast by Type
      12.7.1. 4.6mg/24hr
      12.7.2. 9.5mg/24hr
      12.7.3. 13.3 mg/24hr
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Rivastigmine Transdermal Patches Demand Share, 2019-2029

13. Middle East & Africa Rivastigmine Transdermal Patches Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Rivastigmine Transdermal Patches Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Rivastigmine Transdermal Patches Market Size and Volume Forecast by Application
      13.4.1. Alzheimer's Disease
      13.4.2. Parkinson
      13.4.3. Other
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Rivastigmine Transdermal Patches Market Size and Volume Forecast by Type
      13.7.1. 4.6mg/24hr
      13.7.2. 9.5mg/24hr
      13.7.3. 13.3 mg/24hr
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Rivastigmine Transdermal Patches Demand Share, 2019-2029

14. Competition Landscape
   14.1. Global Rivastigmine Transdermal Patches Market: Market Share Analysis
   14.2. Rivastigmine Transdermal Patches Distributors and Customers
   14.3. Rivastigmine Transdermal Patches Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Novartis Overview Financials Developments Strategic Outlook
      14.4.2. Luye Pharma Overview Financials Developments Strategic Outlook
      14.4.3. ... Overview Financials Developments Strategic Outlook
      14.4.4. COMPANY4 Overview Financials Developments Strategic Outlook
      14.4.5. COMPANY5 Overview Financials Developments Strategic Outlook
      14.4.6. COMPANY6 Overview Financials Developments Strategic Outlook
      14.4.7. COMPANY7 Overview Financials Developments Strategic Outlook
      14.4.8. COMPANY8 Overview Financials Developments Strategic Outlook
      14.4.9. COMPANY9 Overview Financials Developments Strategic Outlook
      14.4.10. COMPANY 10 Overview Financials Developments Strategic Outlook
      14.4.11. COMPANY 11 Overview Financials Developments Strategic Outlook
      14.4.12. COMPANY 12 Overview Financials Developments Strategic Outlook
      14.4.13. COMPANY 13 Overview Financials Developments Strategic Outlook
      14.4.14. COMPANY 14 Overview Financials Developments Strategic Outlook
      14.4.15. COMPANY 15 Overview Financials Developments Strategic Outlook
      14.4.16. COMPANY 16 Overview Financials Developments Strategic Outlook
      14.4.17. COMPANY 17 Overview Financials Developments Strategic Outlook
      14.4.18. COMPANY 18 Overview Financials Developments Strategic Outlook
      14.4.19. COMPANY 19 Overview Financials Developments Strategic Outlook
      14.4.20. COMPANY 20 Overview Financials Developments Strategic Outlook

Our Trusted Clients

Contact Us